New York, USA – April 25, 2022 – Vaccine R&D has been the mainstream of new drug projects and has ushered into a booming era since the outbreak of COVID-19 and the successful development and approval of several vaccines as powerful prevention methods. Creative Biolabs, having been exploring in vaccine field for over a decade, provides first-level solutions regarding vaccine design, validation, and research-use vaccine products, covering full-scale vaccine types that are under intense investigation in the industry, such as cancer vaccine.
“We’ll be exhibiting in the PEGS summit in the coming May,” according to a specialist, “where we’ll showcase our capabilities in immunology areas, such as vaccine, to our familiar faces, and new ones as well.”
In regards to vaccine development, Creative Biolabs’ service shows overall functionality, starting from the vaccine design process that mainly determines the effective target or more specifically, the pathogen and in silico models to be adopted to identify the epitope.
Having preliminarily schemed the vaccine candidate, the project proceeds to the next stage when there will be specialists assisting in identifying the adjuvant candidate through PRR ligands scanning, or customarily synthesizing desired adjuvants. The adjuvant coverage is all-round with superiority over peers, including, mineral salt adjuvant, oil adjuvant, saponin adjuvant, and CpG.
“To err on the side of caution,” noted the specialist, “we do validate the vaccine by evaluating its safety and potency through tests on identity, purity, and stability.”
Diverse assays will be operated to validate those factors. For example, the methods adopted for identity test relate to chromatographic, electrophoresis, and immunological properties. Process-related and product-related impurities that are inherent or derived from equipment and process can be removed as much as possible through methods like chromatography and electrophoresis. And for potency assessment, Creative Biolabs has animal-based assays, cell culture-based assays, and ligand or receptor binding assays to achieve the goal.
The Spring of 2022 is sparkled by the return of in-person events. Creative Biolabs, to gain more brand exposure in the industry, is happy to announce its participation in PEGS Boston Summit in May and the BIO International Convention in June.
“This gonna be a busy year, but we are happy to see that in-person events are back, where we can gain more partnership opportunities.”
Visit https://www.creative-biolabs.com/vaccine to learn more about Creative Biolabs and the upcoming events.
Creative Biolabs is a CRO fully devoted to innovative immunotherapy discovery. With full expertise in immunology disciplines, the scientists at Creative Biolabs have established a systematic service workflow for global researchers exploring vaccines.